Tokaido Health, Inc.

Tokaido Health, Inc. is a US-based company specializing in AI-driven medication management solutions that connect patients with cost-effective medication options, enhancing healthcare efficiency and affordability. Founded in 2025 and headquartered in San Mateo, US, Tokaido Health, Inc. develops an AI-native medication steerage platform.

The company has completed a single funding round, raising USD 25. 00 mn from investors including Norwest, Primary Venture Partners, Next Ventures, and Scrub Capital on May 15, 2026. Tokaido Health offers an AI-native medication steerage platform that optimizes medication spending by connecting patients to affordable options. Key features include infusion site-of-care steerage, biosimilar substitution, formulary optimization, and polypharmacy reconciliation, aimed at enhancing patient outcomes.

The company primarily serves healthcare providers, payers, and organizations focused on reducing medication costs and improving patient adherence across various markets, including the United States. Operating on a business-to-business model, Tokaido Health generates revenue through subscription agreements with healthcare payers and providers, granting access to its suite of medication management tools. Its offerings include an ROI Calculator for assessing potential savings. Pricing structures are tailored to client needs, and Tokaido emphasizes behavioral economics and personalized support in medication cost management.

Tokaido Health plans to utilize the recent USD 25. 00 mn funding to enhance its platform and expand its market presence. Upcoming initiatives include launching new features aimed at improving medication adherence and exploring market opportunities beyond the US. The aim is to enter additional geographical regions by the end of 2026, thereby increasing its impact on medication cost management.